MIM
GBIO

MetLife Investment Management’s Generation Bio GBIO Stock Holding History

MetLife Investment Management’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-430
Closed -$10.6K – 2830
2024
Q3 		$10.6K Sell
430
-2,410
-85% -$63.7K ﹤0.01% 2838
2024
Q2 		$80.1K Buy
2,840
+404
+17% +$13.1K ﹤0.01% 2681
2024
Q1 		$99.1K Buy
+2,436
New +$57.4K ﹤0.01% 2542
2023
Q4 		– Sell
-2,403
Closed -$91.1K – 2842
2023
Q3 		$91.1K Hold
2,403
– – ﹤0.01% 2622
2023
Q2 		$132K Buy
2,403
+818
+52% +$37.5K ﹤0.01% 2520
2023
Q1 		$68.2K Sell
1,585
-1,047
-40% -$50.6K ﹤0.01% 2678
2022
Q4 		$103K Hold
2,632
– – ﹤0.01% 2581
2022
Q3 		$140K Hold
2,632
– – ﹤0.01% 2499
2022
Q2 		$173K Buy
2,632
+653
+33% +$42.7K ﹤0.01% 2420
2022
Q1 		$145K Buy
1,979
+1,636
+477% +$94.8K ﹤0.01% 2523
2021
Q4 		$24.3K Sell
343
-1,218
-78% -$213K ﹤0.01% 2482
2021
Q3 		$391K Hold
1,561
– – ﹤0.01% 1666
2021
Q2 		$420K Hold
1,561
– – ﹤0.01% 1672
2021
Q1 		$444K Buy
1,561
+1,000
+178% +$320K ﹤0.01% 1598
2020
Q4 		$159K Hold
561
– – ﹤0.01% 2102
2020
Q3 		$173K Buy
+561
New +$134K ﹤0.01% 1945

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MetLife Investment Management's GBIO Position: Q4 2024 in Review

MetLife Investment Management sold out of Generation Bio (GBIO) in Q4 2024, closing a stake of 430 shares — an estimated $10.6K sold.

MetLife Investment Management first reported a position in GBIO in Q3 2020 and held it in 16 quarters. The position peaked at $444K in Q1 2021. 78 funds tracked by Wall St. Rank hold GBIO as of Q4 2024.

  • MetLife Investment Management reported no remaining Generation Bio position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 430 Generation Bio shares in Q4 2024, an estimated $10.6K.
  • MetLife Investment Management first reported a position in Generation Bio in Q3 2020 and held it in 16 quarters.
  • MetLife Investment Management's Generation Bio position peaked at $444K in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Generation Bio as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.